Nuveen LLC purchased a new position in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 33,193 shares of the company's stock, valued at approximately $895,000. Nuveen LLC owned approximately 0.18% of USANA Health Sciences as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of USNA. Dimensional Fund Advisors LP grew its stake in shares of USANA Health Sciences by 7.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 773,228 shares of the company's stock worth $27,751,000 after purchasing an additional 55,059 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in USANA Health Sciences by 23.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 173,997 shares of the company's stock worth $4,693,000 after purchasing an additional 33,141 shares in the last quarter. Teacher Retirement System of Texas purchased a new position in USANA Health Sciences during the first quarter worth about $888,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in USANA Health Sciences during the first quarter worth about $870,000. Finally, Jane Street Group LLC grew its position in USANA Health Sciences by 330.0% during the fourth quarter. Jane Street Group LLC now owns 39,979 shares of the company's stock worth $1,435,000 after buying an additional 30,681 shares during the period. Institutional investors and hedge funds own 54.25% of the company's stock.
Insider Activity at USANA Health Sciences
In other USANA Health Sciences news, Director Gilbert A. Fuller sold 1,058 shares of USANA Health Sciences stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $29.10, for a total value of $30,787.80. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider David Mulham Mulham sold 3,515 shares of USANA Health Sciences stock in a transaction that occurred on Wednesday, July 30th. The stock was sold at an average price of $30.26, for a total transaction of $106,363.90. Following the completion of the transaction, the insider owned 9,260 shares in the company, valued at approximately $280,207.60. This trade represents a 27.51% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 5,073 shares of company stock worth $151,982. 0.63% of the stock is currently owned by company insiders.
Analyst Ratings Changes
Separately, Wall Street Zen upgraded shares of USANA Health Sciences from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Two equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $36.00.
Get Our Latest Research Report on USNA
USANA Health Sciences Stock Performance
Shares of NYSE USNA traded up $0.01 during midday trading on Friday, hitting $31.78. The company's stock had a trading volume of 234,152 shares, compared to its average volume of 97,768. USANA Health Sciences, Inc. has a 1-year low of $23.10 and a 1-year high of $41.83. The firm's fifty day moving average price is $31.24 and its 200-day moving average price is $29.57. The firm has a market cap of $580.58 million, a P/E ratio of 17.65, a P/E/G ratio of 1.01 and a beta of 0.64.
USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.54 by $0.20. USANA Health Sciences had a net margin of 3.79% and a return on equity of 9.48%. The firm had revenue of $235.85 million for the quarter, compared to the consensus estimate of $225.20 million. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS. As a group, research analysts predict that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.
About USANA Health Sciences
(
Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Featured Articles
Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
